Skip to content
ClinCalc Pro
Menu
First-Generation Antihistamine — Burns Pruritus / Sedation

Promethazine

Brand names: Phenergan

Promethazine is a sedating first-generation phenothiazine antihistamine with anticholinergic and antiemetic properties, used for allergic symptoms, sedation, and nausea including motion-related and procedural nausea.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It antagonises histamine H1 receptors and also blocks muscarinic and central receptors, producing sedation, antiemesis and relief of histamine-mediated symptoms such as pruritus.

Prescribing in practice

  • Its marked sedative effect is additive with opioids and other central depressants, so use cautiously where these are co-administered and monitor for excessive sedation and respiratory depression.
  • Anticholinergic effects can cause urinary retention, dry mouth, confusion and worsening of narrow-angle glaucoma, with the elderly particularly susceptible to confusion and falls.
  • Promethazine should be avoided in young children because of the risk of respiratory depression; in burns, itch from healing wounds is better managed with non-sedating measures where possible.

Monitoring

Monitor sedation level, anticholinergic effects and respiratory status, especially in older patients and those on concomitant opioids.

Counselling the patient

  • This can help with itching, sickness or sleep but is quite sedating.
  • Take care with drowsiness, particularly alongside strong painkillers.
  • Report difficulty passing urine, marked confusion or excessive sleepiness.

Evidence & guidelines

Promethazine's sedative and anticholinergic profile and its avoidance in young children are detailed in current prescribing references and MHRA advice on sedating antihistamines.

Reference: MHRA Promethazine Safety Update (Under-2s); BBA Burns Pruritus Management Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.